JO
RNTX

John Overdeck’s Rein Therapeutics RNTX Stock Holding History

John Overdeck’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,709
Closed -$48.4K – 5007
2025
Q4 		$48.4K Buy
+41,709
New +$57.5K ﹤0.01% 3941
2021
Q2 		– Sell
-2,255
Closed -$64K – 4665
2021
Q1 		$64K Buy
+2,255
New +$77.3K ﹤0.01% 3732

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

John Overdeck's RNTX Position: Q1 2026 in Review

John Overdeck sold out of Rein Therapeutics (RNTX) in Q1 2026, closing a stake of 41,709 shares — an estimated $48.4K sold.

John Overdeck first reported a position in RNTX in Q1 2021 and held it in 2 quarters. The position peaked at $64K in Q1 2021. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • John Overdeck reported no remaining Rein Therapeutics position as of Q1 2026 after selling out during the quarter.
  • John Overdeck sold 41,709 Rein Therapeutics shares in Q1 2026, an estimated $48.4K.
  • John Overdeck first reported a position in Rein Therapeutics in Q1 2021 and held it in 2 quarters.
  • John Overdeck's Rein Therapeutics position peaked at $64K in Q1 2021.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.